Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bupiwei Xieyinhuo Shengyang Tang is a traditional Chinese medicine (TCM) decoction originally described by Li Dongyuan in the *Pi Wei Lun* (Treatise on the Spleen and Stomach). It is designed to treat 'Yin fire' resulting from spleen and stomach deficiency. The formula typically includes ingredients such as Astragalus, Ginseng, Glycyrrhiza, Coptis, Gypsum, Cimicifuga, Bupleurum, Notopterygium, Atractylodes, and Phellodendron. In modern clinical research, it is being investigated by the Guangdong Provincial Hospital of TCM for the treatment of non-organic insomnia associated with spleen deficiency syndromes. The mechanism is thought to involve the regulation of the brain-gut-axis, intestinal microflora, and immune-inflammatory markers such as cortisol and cytokines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupiwei xieyinhuo shengyang tang.